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Abstract
Cheminformatics approaches such as Quantitative Structure Activity Relationship (QSAR) 
modeling have been used traditionally for predicting chemical toxicity. In recent years, high 
throughput biological assays have been increasingly employed to elucidate mechanisms of 
chemical toxicity and predict toxic effects of chemicals in vivo. The data generated in such assays 
can be considered as biological descriptors of chemicals that can be combined with molecular 
descriptors and employed in QSAR modeling to improve the accuracy of toxicity prediction. In 
this review, we discuss several approaches for integrating chemical and biological data for 
predicting biological effects of chemicals in vivo and compare their performance across several 
data sets. We conclude that while no method consistently shows superior performance, the 
integrative approaches rank consistently among the best yet offer enriched interpretation of models 
over those built with either chemical or biological data alone. We discuss the outlook for such 
interdisciplinary methods and offer recommendations to further improve the accuracy and 
interpretability of computational models that predict chemical toxicity.
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INTRODUCTION
Predictive toxicology is often evaluated at the initial stages of regulatory assessment of 
environmental chemicals or drug discovery to prioritize high-risk chemicals for further 
testing or eliminate such chemicals from further consideration, respectively. In the current 
age of chemical innovation, hundreds to thousands of new chemicals are introduced each 
year [1] creating an urgent need to substantially optimize testing resources and reduce 
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animal use. Current toxicity evaluation protocols increasingly follow a tiered approach 
where chemicals are funneled through in silico, in vitro and in vivo tests in order of 
decreasing throughput [2–4]. Among the in silico methods, cheminformatics and 
bioinformatics have been established as integral parts of toxicity testing, especially at the 
initial stages.
Most of the current computational tools employed in toxicity assessment rely either on 
chemical or biological data. Specifically, cheminformatics approaches attempt to predict 
toxicity from chemical structure alone while ignoring the underlying complex biological 
mechanisms whereas bioinformatics approaches ignore the inherent structural features of 
chemical molecules that may enrich and improve modeling outcomes. In contrast, 
integrative chemical-biological modeling may both improve the prediction performance of 
models and uncover insights previously invisible to either informatics discipline alone. The 
realization that chemical and biological entities interact at various levels of organization in 
the body has spawned the emerging fields of systems chemical biology [5–7], systems 
toxicology [8], or systems pharmacology [9–12]. Several recent reviews [6,10,12–16] have 
focused on the current state of each individual discipline and proposed general schemes to 
integrate cheminformatics and bioinformatics approaches for improved understanding of 
chemical effects on biological systems. Few integrative studies, however, have been 
reported; their paucity is stemming from the lack of both suitable data and integrative 
methods. Nevertheless, a new data landscape for predictive toxicology has emerged due to 
new toxicity testing paradigms such as REACH (Registration, Evaluation and Authorization 
of CHemicals)[17] and Toxicity Testing for the 21st Century [18]. These programs have 
stimulated the proliferation of short-term biological assays employed for testing of growing 
collections of chemicals [19]. These transformative experimental programs offer new 
opportunities for data-driven learning beyond the traditional methods of cheminformatics or 
bioinformatics.
In this review, we reiterate the case for integrative chemical-biological approaches for 
predicting chemical effects in vivo with the ultimate goal of developing safer pharmaceutical 
or industrial chemicals. We assess the strengths and limitations of current predictive 
toxicology efforts based on either cheminformatics or bioinformatics and then discuss 
studies drawing from the two disciplines concurrently. Lastly, we put forth our vision for 
such interdisciplinary methods and offer recommendations to further improve the accuracy 
and interpretability of chemical toxicity prediction models.
CHEMINFORMATICS IN TOXICITY PREDICTION
The availability of large toxicity datasets including hundreds, even thousands of chemicals 
tested as part of ToxCast [20] and Tox21 [21] projects has re-established an interest in 
cheminformatics as a powerful computational approach for predicting chemical toxicity. In 
particular, Quantitative Structure-Activity Relationships (QSAR) modeling is often used as a 
first-line tool for toxicity prediction [22] given that it requires the knowledge of molecular 
structure only. The first QSAR study was published in 1962 [23]; it employed regression 
model correlating plant growth to molecular electronic parameters. Since then, QSAR has 
grown in sophistication to incorporate thousands of chemical descriptors and machine 
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learning methods. Despite its popularity, QSAR modeling has been criticized for poor 
predictivity and interpretability [24–27]. Measures to address weaknesses include OECD 
guidelines [28] and implementation of best practices [29] which advocate careful data 
curation [30] and processing [31], representative sampling of the chemical space [32], 
stringent validation [33] and rational descriptor selection driven by a mechanistic basis to 
simplify interpretation [26].
Despite the above measures, cheminformatics-based prediction of complex toxic phenomena 
has fallen short of expectations. In reality, the relationship between chemical structures and 
toxicity is far more circuitous than the models assume, involving many non-chemical 
factors, e.g., those dependent on complex biological mechanisms. The significance of these 
non-chemical factors depends on the prediction target. Generally, QSAR models are more 
successful at predicting direct chemical-induced outcomes (e.g., mutagenicity) than those 
farther downstream of chemical-initiating events (e.g., carcinogenicity) [34]. Indeed, in 
some cases when large datasets are available, e.g., for mutagenicity (that largely depends on 
molecular interactions between chemical and DNA) the QSAR model accuracy approaches 
that of the experimental Ames assay [34,35]. On the contrary, carcinogenicity has been 
notoriously difficult to predict because of its heterogeneous modes of action and the 
biological host’s adaptive capacity for recovery [34]. One way to account for complex 
biological mechanisms underlying many in vivo effects and achieve better modeling 
outcomes is to integrate multiple biological characteristics of chemicals obtained in short 
term assays with inherent chemical properties of compounds. This emerging integrative 
modeling approach at the interface between bio- and cheminformatics is the main theme of 
this review.
BIOINFORMATICS IN TOXICITY PREDICTION
The post-genome era saw a dramatic rise of bioinformatics. While the field of bioinformatics 
is broad, involving the computational analysis of biological information arising from the 
detailed characterization of an organism at various levels (molecular, cellular, tissue, organ, 
system), this section focuses on applying bioinformatics approaches in toxicology where the 
goal is to study multiple biological perturbations in response to chemical insult.
Simultaneously studying thousands of bioassays offers several advantages: key biomarkers 
can be quickly identified and interactions between the biomarkers characterized, allowing 
for a systems toxicology approach. In drug discovery, the use of diverse bioassay panels 
helps to quickly identify potentially toxic properties (e.g., cytochrome P450 inhibition, 
transporter blockage) which may provide clues into the pathogenesis of undesired effects 
caused by a compound. The bioassay signatures of compounds reflecting certain toxic 
modes of action may be used to probe for compounds with similar mode of action. An 
example of broad biological characterization of drugs is provided by the Japanese 
Toxicogenomics Project where toxicogenomic signatures representative of various types of 
hepatotoxicities (e.g. phospholipidosis, glutathione depletion) have been determined [36]. 
These signatures can be generated for new drugs or drug candidates to predict their long-
term toxicities.
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Advances in assay technology have given rise to a diversity of biological measurements such 
as ‘omics signatures, enzymatic activity, receptor binding affinity, cytotoxicity, and histology 
imaging, allowing toxicologists to probe into both microscopic and macroscopic changes in 
the body. These bioassays may have different predictive power depending on the 
experimental error and biological relevance. High-dimensional ‘omics’ data, especially 
transcriptomics, were shown to predict long term effects such as hepatic tumorigenicity with 
high accuracy [37–40]. In contrast, hundreds of bioassays capturing a large diversity of 
biological characteristics in ToxCast Phase I [41,42], were less predictive [43]. Reasons 
cited by the authors include inadequate experimental fidelity, inadequate biological 
relevance, and poor interspecies extrapolation.
Certain successes notwithstanding, the use of biological data and bioinformatics approaches 
in chemical toxicity prediction is not problem-free. The ease of collecting large-scale 
bioassay data has encouraged fishing expeditions where assays often produce poor quality 
results or may be irrelevant to any toxicity leading to false discoveries. Overly sensitive 
‘omics’ markers may be producing more noise than signal [44]. Countermeasures include 
proper statistical correction (e.g. Bonferroni, Holm) and proper application of biological 
context to draw meaningful conclusions from the data.
The focus on biological information has also regrettably overlooked another important 
dimension of toxicology: chemical information. While bioassays were previously performed 
for a few chemicals due to throughput limitations, it is now possible to perform high 
throughput screening (HTS) for large chemical libraries [45]. Consequently, in vitro toxicity 
data is rich in both biological and chemical information. The underlying chemical patterns, a 
traditional and rich source of data in cheminformatics, have not been capitalized upon by 
bioinformatics. A reasonable approach may be to combine bioinformatics and 
cheminformatics approaches for improved toxicity prediction.
INTEGRATIVE APPROACH COMBINING CHEMINFORMATICS AND 
BIOINFORMATICS
Given the lack of consideration of biological factors in cheminformatics and ignorance of 
chemical structures in bioinformatics, the concurrent study of both biological and chemical 
domains may reveal new discoveries not possible with either domain alone. Such integrated 
approaches recognize that in vivo effects, whether occurring at the cellular, or systemic 
level, emerge from a complex interplay between the chemical inducer and the biological 
host. Chemical factors govern the molecular interactions between the chemical and its 
protein targets. These molecular interactions then initiate a cascade of interactions within the 
cell, organ or organism, eventually giving rise to the observed phenotype as a response to the 
chemical action on the biological system.
The rise of several recent enabling trends facilitates chemical-biological integration. First, 
there is an increased demand and acceptance of toxicity prediction from in silico and in vitro 
tests instead of in vivo tests in efforts to boost testing throughput, improve animal welfare 
and deepen our understanding of the toxicological mechanisms; these new paradigms are 
accelerated by regulatory programs such as REACH[17] and Toxicity Testing for the 21st 
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Century [18]. Consequently, in large-scale programs such as ToxCast [20], Tox21 [21], and 
Molecular Libraries Initiative [46] thousands of chemicals are tested in thousands of 
biological assays, with the results of these HTS studies placed in publicly available 
repositories such as PubChem [47] or ToxNet [48]. For instance, toxicity databases now 
contain large amounts of chemical and biological information through data consolidation 
(e.g. ACToR [19], Bio2RDF [49], OpenPHACTS[50], PredPharmTox [51]; see [11] for table 
of databases).
The unprecedented growth of data in terms of the number and diversity of chemicals, and 
comprehensive biological assay characterization has afforded new research opportunities for 
both cheminformatics and bioinformatics. Where previously only a few chemicals were 
tested, the new data landscape has reinvigorated interest in cheminformatics as a means of 
transforming latent chemical patterns into useful chemical insights. On the other hand, the 
deeper biological assay characterization allows one to learn more about each chemical in 
terms of underlying biological mechanisms of its in vivo effects. Yet, sticking to the 
approaches of only chemical or biological modeling is unlikely to take full advantage of the 
richness of the modern data streams that effectively capture chemical-biological interactions.
The many parallels between bioinformatics and cheminformatics provide points of 
commonality to facilitate integration. Underpinning both fields are statistical techniques 
relating molecular features of a chemical to its biological effects. These statistical 
relationships rely on the similarity principle which expects chemicals similar in their 
molecular feature profiles to exhibit similar behavior. The key difference between 
bioinformatics and cheminformatics here lies in the choice of appropriate molecular 
features, i.e., either ‘omics’ profiles assayed by HTS or molecular structural information 
represented by chemical descriptors. The statistical techniques, whether as simple as read-
across or as complex as machine learning, are equally applicable to both fields.
A simple means of integration is to apply existing statistical methods to both chemical and 
biological types of molecular features. Another way is to merge chemical models with 
biological models. Other approaches may be less straightforward, strategically combining 
chemical structures and biological assays such that the two data sources compensate for each 
other’s shortcomings and the complementary information between them is maximally used. 
Generally, modeling studies combining chemical and biological data have reported increased 
predictivity and interpretability (Table 1). Integrative chemical-biological approaches 
attempted in those studies may be broadly classified into three types: 1) data pooling (Fig. 
1A), 2) model pooling (Fig. 1B), or 3) other integrative strategies that exploit the multi-
domain data (e.g. hierarchical local models shown in Fig 1C).
Data pooling
In data pooling, disparate data sources are pooled to create a larger, “hybrid” data matrix for 
modeling by existing statistical methods. This has been aided by the growing availability of 
consolidated databases. Besides HTS assays, new data streams can include text annotations 
automatically mined from biomedical literature (ChemoText [52]), product labels (SIDER) 
[53–55] and clinical notes [56,57].
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Table 1 lists several studies predicting toxicity from pooling various data streams. Generally, 
prediction performance improved after pooling, although several exceptions exist. Among 
the exceptions, a comprehensive modeling of 60 in vivo toxicities based on chemical 
structures and/or in vitro assays of ToxCast phase I data described limited if any success 
with data pooling models [43]. Several other studies reported that models’ accuracy dropped 
when chemical descriptors were added on top of bioassay data such as toxicogenomics [58], 
hepatocyte imaging indicators [59], and protein targets [60]. Noteworthy, all four of the 
mentioned studies [43,58–60] employ rather small and structurally diverse sets of chemicals. 
Understandably, chemical models performed worse than biological ones [58–60], while in 
the ToxCast study [43] both were similarly poor. Thus, we caution against favoring either 
chemical or biological model as either performance will depend on many contributing 
factors such as the size and structural diversity of the chemical datasets and quality of 
biological data. Where biological data included considerable noise, additional data treatment 
may improve prediction outcomes from data pooling. For example, Sedykh et. al. [61] 
introduced a noise filter to transform cytotoxicity profiles into dose-response curve 
parameters that, when pooled with chemical structures, provided more accurate models of 
rat acute toxicity than the original cytotoxicity assay values.
Model pooling
Another way of integrating chemical and biological data is by meta-analysis or ensemble 
modeling, which pools individual predictions from several models into a final predicted 
value. The main benefit of ensemble modeling, i.e., increased predictivity, arises when the 
constituent models compensate for the errors of one another [62]. The notion that many 
models are better than one is best exemplified by the random forest algorithm which seeks 
the consensus vote of numerous constituent decision tree models within its “forest” [63]. In 
the case of toxicity modeling, chemical-based models and biological-based models may be 
pooled such that their consensus vote provides the final prediction outcome.
Such model pooling is already widely practiced in regulatory chemical risk assessment and 
drug discovery during where all the prediction outcomes from various toxicity models are 
weighted before arriving at a consensus decision [64,65]. For example, drugs must not 
contain structural alerts of mutagenicity and their bioassay profiles must indicate the lack of 
inhibitory effects on the major cytochrome P450 enzymes required for drug metabolism.
Ensemble modeling can be used in one of two ways. One approach is to require that all the 
constituent models for a compound point to the same prediction outcome so that the end 
point toxicity can be estimated with higher confidence. Alternatively, one can argue that 
ensemble modeling enlarges the modelable space of molecules such that compounds that 
cannot be predicted with confidence by one model receive their prediction from another 
model. In the first case, Vilar et. al. showed increased precision when a chemical similarity 
model was pooled with a model based on clinical notes [66,67]. In the second case, an 
ensemble chemical-biological model may compensate for the invalid predictions by the 
QSAR model outside its chemical coverage area. However, ensemble models may not 
always outperform their constituent chemical and biological models, as we have 
demonstrated recently using four different data sets [68]. Especially where a constituent 
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model is already highly predictive, adding another inferior model may lead to reduced 
predictive power of the consensus model. Thus, model pooling should be done with care 
paying attention to relative predictive power of each constituent model.
Other integrative methods
The mixed success of pooling data or models has led to the development of innovative 
approaches that leverage prior knowledge of the data structure and optimize the use of the 
disparate data sources. Network modeling that allows the simultaneous study of disparate 
entities (chemicals, targets and phenotypes) is employed increasingly [69]. In a graph 
representation (Figure 2), entities appear as nodes connected by edges if they are associated. 
Association may be defined in terms of direct physical interaction (e.g., drug binds to target) 
or statistically (e.g., disproportionately more reports of adverse effect with drug). In such 
way modeling, the goal is to infer new associations among pairs of entities through indirect 
associations. This is best illustrated by Swanson’s ABC paradigm [70] in which association 
between entities A and C is inferred if there exist direct associations between pairs A–B and 
B–C (Figure 2A). Networks may be further enriched by chemical similarity [71,72], protein 
sequence similarity [73], or side effect similarity [74] such that novel inferences with higher 
confidence can be drawn (Figure 2B [75]). Associations successfully predicted in recent 
studies include those of phenotype-target [72], chemical-phenotype [76,77], and chemical-
target [74,78,79] type. For examples of broader efforts to infer more than a single type of 
associations, the readers are referred to several recent studies [69,71,80].
Strategic use of biological data to stratify data sets into distinct clusters for further separate 
or localized modeling can be a promising direction. Zhu et. al.[81] described a two-step 
hierarchical approach, in which the authors first stratified compounds by their in-vitro/in-
vivo correlation into two classes , i.e., a group of compounds whose in vitro/in vivo data 
correlated and a remaining group where no correlation was observed. The authors then built 
a classification model using this biologically-inferred strata and then also built stratum-
specific QSAR models. It has been shown that such a hierarchical workflow where a new 
compound was first assigned to one of the two strata followed by the prediction using 
stratum-specific models afforded overall improved prediction accuracy [81,82]. Other 
strategic use of biological data to stratify data sets into clusters for localized modeling was 
also attempted by Lounkine et al. [83] who clustered compounds by chemical similarity and 
their bioactivity. Analogously, chemical structural data can provide useful input for 
biological modeling. For example, pharmacokinetics parameters, where unknown, may be 
estimated by QSAR models from molecular structure and then used in subsequent 
physiological-based models to simulate chemical toxicity in the body [84–86].
Another recently published novel integrative method, quantitative chemical-biological read-
across (CBRA) [68], relied on the principles of k nearest neighbors. The CBRA approach 
can be viewed as an ensemble model, in which chemical- and biological-based predictions 
for a new chemical are weighted by similarity to known both chemical and biological 
analogs. This enhanced pooling of chemical and biological neighbors helps to maximize the 
complementarities between chemical and biological data. In particular, conflicting 
predictions from chemical and biological models are resolved, resulting in overall 
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predictivity gains. The authors compared CBRA with two other types of integrative 
approaches (data pooling, model pooling) on four data sets and found that none of the three 
approaches was markedly superior to others. We believe that this holds true in general, and 
no single integrative technique is likely to solve all modeling problems. Instead, this we 
emphasize the importance of employing set of modeling tools from which most appropriate 
and expedient ones can be selected and attempted for each complex dataset.
RECOMMENDATIONS AND OUTLOOK
The mixed success of using both chemical and biological features suggest the following 
methodological implications for predicting chemical effects. First, consider information-rich 
and biologically relevant assays as features. Information-rich assays such as gene expression 
may have more predictive value than non-descript assays measuring binary biological 
responses (e.g., binding/nonbinding to a target protein) [87]. The bioassays may be selected 
rationally according to biological pathways to reflect their relevance to the in vivo effect 
[43,88]. Third, careful variable selection [43], modeling and validation according to OECD 
(Q)SAR principles [28] are necessary to ensure robust and accurate models [29]. Lastly, 
consider the choice of modeling methods. Irrelevant variables may affect some classification 
methods more than others. For example, instance-based methods including CBRA are more 
susceptible to irrelevant variables while others such as random forest can better tolerate 
noisy variables [89,90].
A multidisciplinary systems approach is increasingly seen as the key solution to translating 
molecular and preclinical insights into desired clinical outcomes of drug use. In addition to 
addressing the issue of data quality, further gains through methodological innovations and 
cohesive integration of the various disciplines will be necessary. Scientists who develop and 
employ such approaches need to have profound understanding of both the data and data-
analytical techniques. The ingredients for such multi-disciplinary efforts are unlikely to 
occur organically and will require deliberate efforts to foster a collaborative environment. As 
more data come online and advances in assay technologies reduce experimental variability, 
we expect integrative approaches to play a greater role in toxicology and drug discovery 
applications.
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Integrative chemical-biological approaches for toxicity prediction.
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Knowledge-based relationships between objects (e.g., drugs, targets, and activity 
phenotypes) form an object network that allows new inferences. (A) Swanson ABC 
paradigm, adapted from [52]; (B) Network enriched by similarity within classes of objects 
(solid edges) boost new inferences (dotted edges), adapted from [75].
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Table 1
Integrative approaches used for toxicity prediction
Prediction target Data sources Type Studies
Rat LD50 Chemical structure,
Cytotoxicity
Data pooling [91]
Rat LD50 Chemical structure,
Dose-cytotoxicity profiles
Data pooling [61]
Rat LD50 Chemical structure,
Cytotoxicity
Integrative method [81]
Rat reproductive toxicity Chemical structure,
In vitro assays
Integrative method [82]







Drug hepatotoxicity Chemical structure,
Hepatocyte imaging assays
Data pooling [59]
In vivo toxicities Chemical structure,
In vitro assays
Data pooling [43]
Drug properties Chemical structure,
Bioactivity
Integrative method [83]
Adverse drug reactions Chemical structure,
Electronic health records
Model pooling [66, 67]
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